The 3rd quarter edition of our ReMarks newsletter is out, including:

  • Supreme Court decision on Actavis v Eli Lilly (Doctrine of Equivalents)
  • Working with the new EU Trade Mark Regulation
  • Brexit: A first look at the UK's EU Withdrawal Bill's implications for IP
  • New PPH program between Malaysia and EPO
  • Brexit: European Commission publishes position paper on IPRs
  • Canadian Federal Court of Appeal Indicates that a "Promise" is not the Solution
  • The "plausibility" requirement at the EPO
  • Warner-Lambert's pain continues in Singapore 
  • EPO engages with Unitary Patents 

To view the full article please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.